Midtveisevaluering - Farivar Fathian
Midtveisevaluering for ph.d.-graden ved Universitetet i Bergen for kandidat Farivar Fathian
Hovedinnhold
Abstract
The PhD project uses data from 2 large medication trials , The Bergen Psychosis Projects 1 and 2, (BP 1 and BP2) with inclusion of patients with schizophrenia and related psychosis disorders. The BP1 was conducted between 2003-2010 at Haukeland University Hospital, and included a total of 226 patients who were randomized to the antipsychotic drugs olanzapine, quetiapine, risperidone or ziprasidone with a 2-years follow-up.
The BP2 is an ongoing multicentre study with Bergen as project leader and with the highest inclusion rate, in addition to Stavanger, Innsbruck and Trondheim. The inclusion has taken place in a period of 5 years 2011-2016, with a total of 155 randomized participants. The BP2 compares three first-line antipsychotic drugs amisulpride, aripiprazole and olanzapine in a pragmatic, rater-blind, randomized trial (RCT) with a 1-year follow-up. The projects have been funded independently of the pharmaceutical industry.
The objectives in this PhD are to study association between inflammatory markers and cognitive function in patients with acute psychosis. The study will also compare antipsychotic effects on changes in the level of inflammatory markers and cognitive functions in schizophrenia spectrum disorders.